GI-PRO™ is Mānuka Performance's proprietary honey snap — a validated, PolySure™-certified Mānuka & Rewarewa honey matrix combined with 2 billion CFU of BC30™ (Bacillus coagulans GBI-30, 6086®) per serve. One daily snap, no pills, no powders — a science-backed, FDA-compliant digestive health product built for the US wellness consumer.
The honey isn't a flavour vehicle — it's an active co-factor. Naturally occurring prebiotic carbohydrates and polyphenols prime the gut and enhance BC30™'s delivery, while our MPS PolySure™ standard certifies the polyphenol matrix on every batch. This is what separates GI-PRO™ from a probiotic capsule or a jar of honey alone.
A single formulation, built for one job: daily, defensible, science-backed digestive health support for the US consumer.
Each GI-PRO™ snap combines New Zealand Mānuka and Rewarewa honey — chosen for their naturally occurring prebiotic carbohydrates, minerals, and polyphenols — with 2 billion CFU of BC30™ (Bacillus coagulans GBI-30, 6086®), a safe, spore-forming, science-backed probiotic strain.
Positioned for health-conscious adults managing everyday gut discomfort, bloating, and digestive regularity — a mess-free, no-pills-no-powders format taken anywhere, once a day.
GI-PRO™'s defensibility comes from validating both halves of the formulation independently, then proving they work better together than either does alone.
Our advantage isn't a brand story — it's structural, and it deepens every year through ongoing research.
This moat compounds through ongoing work: an active, ethics-approved RCT on GI-PRO™ gut microbiome outcomes, an MPI-funded polyphenol validation programme covering 100+ honey varieties, and an untargeted screening programme that has already identified ten putative novel compounds across 112 honey samples. Every study adds a layer that a competitor without our data, our partnerships, and our provenance cannot replicate.
Every claim GI-PRO™ makes is built in stages — declared nutrients, to validated ingredient identity, to FDA-recognized functional claims — so the final consumer-facing statement is defensible end to end.
These statements have not been evaluated by the Food and Drug Administration. GI-PRO™ is not intended to diagnose, treat, cure, or prevent any disease. Claims sign-off and label review are managed by Dr Lillian Morton PhD, Chief Science Officer.
Gut health is not a niche — it's the highest-growth segment in the US supplement category we track, and GI-PRO™ is purpose-built for the consumer driving that growth.
The purchase driver is convenience as much as efficacy: a single, great-tasting, mess-free daily dose taken anywhere — no pills, no powders, no prep — delivered in a honey format consumers already recognize and enjoy.
| Segment | Market Size (TTM) | YoY Growth | Seasonality |
|---|---|---|---|
| Gut Health / Probiotics (Amazon) | $314M | +51% | High |
Gut Health / Probiotics is the fastest-growing of the eight Amazon wellness segments Mānuka Performance tracks via Channel Key (Cobalt by Jungle Scout data), and one of only two showing strong double-digit growth. Broader context: the US Vitamins, Minerals & Supplements market exceeds $60B; the global functional food and wellness market exceeds $400B; and the gut health category overall is growing 7–10% annually. GI-PRO™ sits directly inside the single highest-growth segment in our addressable market.
On Amazon, roughly $8–12 per unit goes to platform fees; on D2C, those fees do not exist — at GI-PRO™'s ~$69 price point, that represents a 17–27 percentage-point margin improvement on direct transactions, reinforcing why Amazon-first, D2C-retained is the deliberate sequencing for this product.
We are consolidating manufacturing and commercial infrastructure from the Bay of Plenty into Auckland — New Zealand's largest economic centre and most connected international gateway — building toward pharmaceutical-grade (GMP) production.
BC30™ is a registered trademark of Kerry Group plc, supplied under license. MPS PolySure™ is not an open-access standard — it is our proprietary validation framework, applied to every GI-PRO™ batch.
GI-PRO™'s R&D programme is deliberately structured to move up the evidence ladder over time — from consumer digestive-health claims today, toward mechanistic gut-microbiome evidence.
This is a deliberate sequencing choice, not a promise of a therapeutic outcome: consumer revenue funds the science, and the science funds deeper characterisation of GI-PRO™'s honey-and-probiotic matrix.